Dr. John T. Dellacroce, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,247
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Louisiana State University School of Medicine in Shreveport
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
AR license E-7012
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwest Medical Center-Springdale Springdale, AR
Medical groups
- Retina Center of Arkansas PLLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,247
- Services billed
- 59,531
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 25,560 | 98 |
| Imaging of retina | 2,364 | 970 |
| Injection, aflibercept, 1 mg | 2,264 | 275 |
| Injection of drug into eye | 1,371 | 329 |
| Photography of the retina | 679 | 431 |
| Established patient complete exam of visual system | 599 | 538 |
| Established patient office or other outpatient visit, 20-29 minutes | 454 | 356 |
| Established patient office or other outpatient visit, 30-39 minutes | 382 | 301 |
| New patient complete exam of visual system | 165 | 165 |
| New patient office or other outpatient visit, 45-59 minutes | 155 | 155 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brimonidine Tartrate Other prescribers in Fayetteville, AR | 245 |
| Prednisolone Acetate Other prescribers in Fayetteville, AR | 182 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Fayetteville, AR | 94 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Fayetteville, AR | 56 |
| Timolol Maleate Other prescribers in Fayetteville, AR | 30 |
| Latanoprost Other prescribers in Fayetteville, AR | 26 |
| Dorzolamide Hcl Other prescribers in Fayetteville, AR | 18 |
| Diazepam Other prescribers in Fayetteville, AR | 15 |
| Lumigan (bimatoprost) Other prescribers in Fayetteville, AR | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 17 payments worth $553 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $196 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $101 |
| Apellis Pharmaceuticals, Inc. | $77.29 |
| Genentech USA, Inc. | $49.08 |
| Astellas Pharma US Inc | $40.37 |
| Harrow Eye, LLC | $33.62 |
| Genentech, Inc. | $19.14 |
| Boston Scientific Corporation | $18.57 |
| Food and Beverage | $553 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $25,448 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.